Research

Cellular

SGLT-2 inhibitors and GLP-1 receptor agonists demonstrate significant benefits beyond glucose control.

Practitioners should consider these medications for benefits beyond glycemic control.

StrongSupportsmedium confidence
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in particular have demonstrated significant benefits beyond glucose control.
Natasha P. Malkani et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2022

Why this rating

The claim is supported by recent studies mentioned in the abstract.

Source

Utilizing type 2 diabetes medications outside glycemic parameters – where are we headed?

Natasha P. Malkani et al. · Current Opinion in Endocrinology Diabetes and Obesity · 2022

DOI 10.1097/med.0000000000000787

reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →